| Literature DB >> 35727562 |
Sang-Won Kang1, Seonghee Kang2, Boram Lee1, Changhoon Song1, Keun-Yong Eom1, Bum-Sup Jang1, In Ah Kim1, Jae-Sung Kim1, Woong Cho3, Dong-Suk Shin4, Jin-Young Kim5, Jin-Beom Chung1.
Abstract
This study is to investigate the optimal treatment option for synchronous bilateral breast cancer (SBBC) by comparing dosimetric and radiobiological parameters of intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) plans using single and dual isocenters. Twenty patients with SBBC without lymph node involvement were selected retrospectively. Four treatment plans were generated for each patient using the Eclipse treatment planning system (Varian Medical System, Palo Alto, CA, USA) following two delivery techniques with two isocenter conditions-IMRT using a single isocenter (IMRT_Iso1), VMAT using a single isocenter (VMAT_Iso1), IMRT using dual isocenters (IMRT_Iso2), and VMAT using dual isocenters (VMAT_Iso2). A dose of 42.56 Gy in 16 fractions was prescribed for the planning target volume (PTV). All plans were calculated using the Acuros XB algorithm and a photon optimizer for a 6-MV beam of a Vital Beam linear accelerator. PTV-related dosimetric parameters were analyzed. Further, the homogeneity index, conformity index, and conformation number were computed to evaluate plan quality. Dosimetric parameters were also measured for the organs at risk (OARs). In addition, the equivalent uniform dose corresponding to an equivalent dose related to a reference of 2 Gy per fraction, the tumor control probability, and the normal tissue complication probability were calculated based on the dose-volume histogram to investigate the radiobiological impact on PTV and OARs. IMRT_Iso1 exhibited similar target coverage and a certain degree of dosimetric improvement in OAR sparing compared to the other techniques. It also exhibited some radiobiological improvement, albeit insignificant. Although IMRT_Iso1 significantly increased monitor unit compared to VMAT_Iso1, which is the best option in terms of delivery efficiency, there was only a 22% increase in delivery time. Therefore, in conclusion, IMRT_Iso1, the complete treatment of which can be completed using a single setup, is the most effective method for treating SBBC.Entities:
Keywords: dosimetric parameters; intensity-modulated radiotherapy; radiobiological parameters; synchronous bilateral breast cancer; volumetric modulated arc therapy
Mesh:
Year: 2022 PMID: 35727562 PMCID: PMC9359036 DOI: 10.1002/acm2.13706
Source DB: PubMed Journal: J Appl Clin Med Phys ISSN: 1526-9914 Impact factor: 2.243
Dose constraints to target volume and organs at risk for planning synchronous bilateral breast cancer (SBBC)
| Structure | Dose constraints |
|---|---|
| PTVa |
|
| Left lung |
|
| Right lung |
|
| Heart |
|
| Left anterior descending artery |
|
aPlanning target volume.
FIGURE 1Beam arrangements of (a) IMRT_Iso1, (b) IMRT_Iso2, (c) VMAT_Iso1, and (d) VMAT_Iso2 according to the conditions of two delivery techniques and two isocenters
The radiobiological parameters used for synchronous bilateral breast cancer (SBBC) irradiation
| Organ |
| γ50 | TD50 (Gy) | TCP50 (Gy) | Alpha–beta ratio |
|---|---|---|---|---|---|
| PTVa | −7.2 | 2 | 28 | 4 | |
| Lung | 1 | 2 | 24.5 | 3.9 | |
| Heart | 3 | 3 | 48 | 2 |
aPlanning target volume.
FIGURE 2Dose distributions on an axial view of (a) IMRT_Iso1, (b) IMRT_Iso2, (c) VMAT_Iso1, and (d) VMAT_Iso2 plans for one patient case
FIGURE 3Mean dose–volume histogram (DVH) of planning target volume (PTV) for four treatment regimens of 20 synchronous bilateral breast cancer (SBBC) patients
FIGURE 4Mean dose–volume histogram (DVH) of (a) left lung, (b) right lung, (c) heart, and (d) left anterior descending (LAD) for four treatment regimens of 20 synchronous bilateral breast cancer (SBBC) patients
The comparison of dosimetric parameters to planning target volume (PTV) in four treatment regimens according to the conditions of two delivery techniques and two isocenters
| Index | IMRT_Iso1 | IMRT_Iso2 | VMAT_Iso1 | VMAT_Iso2 | |
|---|---|---|---|---|---|
| PTV |
| 47.89 ± 0.61 | 48.28 ± 1.04 | 48.88 ± 1.01 | 48.39 ± 0.57 |
|
| 43.95 ± 0.29 | 43.82 ± 0.21 | 43.75 ± 0.19 | 44.09 ± 0.16 | |
|
| 36.61 ± 1.56 | 34.68 ± 3.67 | 32.84 ± 2.30 | 34.42 ± 1.72 | |
|
| 99.70 ± 0.24 | 99.53 ± 0.56 | 97.03 ± 1.74 | 98.78 ± 0.85 | |
| HIa | 0.11 ± 0.01 | 0.11 ± 0.01 | 0.15 ± 0.02 | 0.13 ± 0.01 | |
| CIb | 1.00 ± 0.00 | 1.00 ± 0.01 | 0.97 ± 0.02 | 0.99 ± 0.01 | |
| CNc | 0.84 ± 0.03 | 0.83 ± 0.03 | 0.84 ± 0.04 | 0.84 ± 0.04 |
aHomogeneity index.
bConformity index.
cConformation number.
The comparison of dosimetric parameters to organs at risk (OARs) in four treatment regimens
| Organs | Index | IMRT_Iso1 | IMRT_Iso2 | VMAT_Iso1 | VMAT_Iso2 |
|---|---|---|---|---|---|
| Lt lung |
| 15.12 ± 0.77 | 15.08 ± 0.73 | 16.00 ± 1.16 | 16.59 ± 1.05 |
|
| 77.40 ± 4.71 | 72.77 ± 3.77 | 88.73 ± 5.80 | 91.40 ± 3.82 | |
|
| 57.55 ± 6.51 | 59.23 ± 4.79 | 65.85 ± 7.50 | 64.10 ± 5.11 | |
|
| 27.67 ± 3.54 | 27.41 ± 3.86 | 28.64 ± 4.13 | 31.35 ± 3.60 | |
|
| 16.67 ± 2.99 | 14.58 ± 3.22 | 13.72 ± 2.15 | 13.32 ± 2.25 | |
| Rt lung |
| 15.38 ± 0.37 | 15.49 ± 0.72 | 15.87 ± 1.45 | 16.86 ± 1.37 |
|
| 79.62 ± 5.47 | 79.07 ± 2.82 | 82.74 ± 2.42 | 83.88 ± 3.28 | |
|
| 60.87 ± 6.43 | 59.79 ± 5.84 | 64.71 ± 7.40 | 66.54 ± 5.51 | |
|
| 28.07 ± 3.27 | 26.66 ± 4.18 | 29.63 ± 4.85 | 30.55 ± 5.38 | |
|
| 16.70 ± 3.59 | 16.22 ± 3.53 | 14.73 ± 3.23 | 13.23 ± 2.47 | |
| Heart |
| 10.34 ± 2.47 | 9.05 ± 0.59 | 9.85 ± 1.13 | 11.08 ± 0.84 |
|
| 8.96 ± 6.82 | 8.69 ± 7.29 | 6.30 ± 4.15 | 11.34 ± 5.36 | |
| LADa |
| 19.31 ± 4.36 | 18.25 ± 5.22 | 18.01 ± 4.62 | 18.17 ± 4.26 |
|
| 16.33 ± 18.17 | 15.56 ± 20.18 | 13.48 ± 13.14 | 16.09 ± 15.41 |
aLeft anterior descending.
The tumor control probability (TCP) and the equivalent uniform dose (EUD) value for planning target volume (PTV) and the normal tissue complication probability (NTCP) and EUD values for organs at risk (OARs)
| Organs | Index | IMRT_Iso1 | IMRT_Iso2 | VMAT_Iso1 | VMAT_Iso2 |
|---|---|---|---|---|---|
| PTV | EUD2Gy (Gy) | 49.17 ± 0.45 | 48.97 ± 0.31 | 48.76 ± 0.46 | 49.21 ± 0.32 |
| TCP (%) | 98.90 ± 0.08 | 98.87 ± 0.06 | 98.79 ± 0.09 | 98.91 ± 0.06 | |
| Lt lung | EUD2Gy (Gy) | 13.55 ± 0.76 | 13.62 ± 0.72 | 14.44 ± 1.72 | 15.09 ± 2.33 |
| NTCP (%) | 0.76 ± 0.37 | 0.84 ± 0.49 | 1.20 ± 1.18 | 1.09 ± 1.40 | |
| Rt lung | EUD2Gy (Gy) | 13.94 ± 0.47 | 14.13 ± 0.80 | 14.47 ± 1.44 | 15.52 ± 1.43 |
| NTCP (%) | 1.12 ± 0.31 | 1.33 ± 0.69 | 1.93 ± 2.06 | 3.10 ± 2.18 | |
| Heart | EUD2Gy (Gy) | 11.63 ± 2.61 | 12.64 ± 2.75 | 10.61 ± 2.22 | 12.85 ± 2.21 |
| NTCP (%) | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 |
The comparison of the delivery parameters for the four treatment regimens
| Index | IMRT_Iso1 | IMRT_Iso2 | VMAT_Iso1 | VMAT_Iso2 |
|---|---|---|---|---|
| MUa | 2016 ± 63 | 2469 ± 86 | 1211 ± 23 | 1483 ± 54 |
| Delivery time (s) | 210 ± 39 | 251 ± 51 | 172 ± 11 | 208 ± 28 |
aMonitor unit.